CAMP and neoplasm: Blockage of versican V1 by shRNA knockdown, in tumor cells, inhibited TLR2/6, VDR, Cyp24, Cyp27B1, and hCAP18/LL-37 induction, as well as tumor cell proliferation and invasiveness.